Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules that are involved in the growth, progression and spread of cancer.
Each personalized gene profile provides information on current FDA-approved treatment options proven effective for the tumor DNA mutations identified.
Sources: cancer.gov and fda.gov
ABL1
Bosutinib
Busulfan
Dasatinib
Imatinib
Nilotinib
Omacetaxine
Ponatinib
ALK
Ceritinib
Crizotinib
BRAF
Dabrafenib
Trametinib
Vemurafenib
EGFR
Afatinib
Cetuximab
Erlotinib
Gefitinib
Lapatinib
Panitumumab
Vandetanib
ERBB2
Ado-Trastuzumab
Emtansine
Everolimus
Lapatinib
Pertuzumab
Trastuzumab
FLT3
Cabozantinib
Ponatinib
JAK2
Ruxolitinib
JAK3
Tofacitinib
KIT
Axitinib
Cabozantinib
Imatinib
Pazopanib
Regorafenib
Sorafenib
KRAS
Cetuximab
Panitumumab
MET
Cabozantinib
Crizotinib
PDGFRA
Axitinib
Imatinib
Pazopanib
Sorafenib
RET
Cabozantinib
Regorafenib
Vandetanib
ALK GENE FUSION
Alectinib
Brigatinib
Crizotinib
Ceritinib
ROS1 GENE FUSION
Crizotinib
PD-L1 EXPRESSION
Pembrolizumab
Nivolumab
MSI-H
Pembrolizumab
Nivolumab
Genes below have no FDA-approved drugs at this time.
AKT1
APC
CDKN2A
CTNNB1
EZH2
FBXW7
FGFR1
FGFR2
GNA11
GNAQ
HRAS
IDH1
MPL
NOTCH1
NPM1
NRAS
PIK3CA
PTEN
RB1
SMAD4
SRC
STK11
TP53